Bo Hwa Sohn

Title: Bo Hwa Sohn: Innovator in Cancer Diagnosis and Treatment

Introduction

Bo Hwa Sohn is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of cancer research, particularly in the diagnosis and treatment of liver cancer. His innovative approach utilizes epigenetic markers to enhance the accuracy of cancer prognosis.

Latest Patents

Bo Hwa Sohn holds a patent for a method that focuses on the diagnosis and prognosis of cancers using a specific epigenetic marker. This method involves a single CpG site in the TTP (Tristetraprolin) promoter. The patent details a technique for diagnosing liver cancer by measuring the methylation of a specific residue in the nucleic acid sequence. This invention not only aids in the diagnosis of liver cancer but also offers potential treatment options by regulating the epigenetic status of the cancer cells.

Career Highlights

Sohn is affiliated with the Korea Research Institute of Bioscience and Biotechnology, where he conducts his research. His work has been instrumental in advancing the understanding of cancer biology and developing new diagnostic tools. His innovative methods have the potential to improve patient outcomes significantly.

Collaborations

He collaborates with notable colleagues, including Young Il Yeom and In Young Park, who contribute to his research endeavors. Their combined expertise enhances the quality and impact of their work in the field of cancer research.

Conclusion

Bo Hwa Sohn is a key figure in the innovation of cancer diagnosis and treatment. His patented methods represent a significant advancement in the fight against cancer, particularly liver cancer. His contributions continue to pave the way for future research and development in this critical area of healthcare.